5-甲基异恶唑-3-羧酸甲酯 | 19788-35-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-甲基异恶唑-3-羧酸甲酯
• 中文别名: 5-甲基异唑-3-羧酸甲酯；5-甲基异噁唑-3-羧酸甲酯；5-甲基异恶唑-3-羧酸
• 英文名称: methyl 5-methylisoxazole-3-carboxylate
• 英文别名: methyl 5-methyl-1,2-oxazole-3-carboxylate
• CAS: 19788-35-3
• 化学式: C₆H₇NO₃
• mdl: MFCD00015895
• 分子量: 141.126
• InChiKey: MVHHQOCEOUNTID-UHFFFAOYSA-N

物化性质

• 熔点：
  90-92 °C
• 沸点：
  125°C 11mm
• 密度：
  1.179±0.06 g/cm3(Predicted)
• 闪点：
  125°C/11mm
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）
• 稳定性/保质期：

  如果按照规则使用和储存，则不会分解。

  避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  52.3
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 安全说明：
  S24/25
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  在密封的贮藏器中存放，并置于阴凉、干燥处。

SDS

Name:	Methyl 5-methylisoxazole-3-carboxylate Material Safety Data Sheet
Synonym:	None Known
CAS:	19788-35-3

Section 1 - Chemical Product MSDS Name:Methyl 5-methylisoxazole-3-carboxylate Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
19788-35-3	Methyl 5-methylisoxazole-3-carboxylate	98	243-311-9

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid.
Skin:
In case of contact, flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical aid if irritation develops and persists. Wash clothing before reuse.
Ingestion:
If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 19788-35-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystalline powder
Color: white to off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H7NO3
Molecular Weight: 141.13

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Acids, bases, reducing agents, oxidizing agents.
Hazardous Decomposition Products:
Hydrogen cyanide, carbon monoxide, oxides of nitrogen, carbon dioxide, nitric acid.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 19788-35-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Methyl 5-methylisoxazole-3-carboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 19788-35-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 19788-35-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 19788-35-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学性质：结晶（苯），熔点为98-99℃。

用途：作为磺胺甲基异噁唑的中间体。

生产方法：可通过乙酰丙酮酸甲酯与盐酸羟胺环合而制得。

反应信息

• 作为反应物：
  描述：

  5-甲基异恶唑-3-羧酸甲酯 在 盐酸 、 一水合肼 、 sodium nitrite 作用下， 反应 2.0h， 生成 5-methyl-isoxazole-3-carbonyl azide
  参考文献：
  名称：

  Freri, Gazzetta Chimica Italiana, 1932, vol. 62, p. 457,461

  摘要：

  DOI：
• 作为产物：
  描述：

  乙酰丙酮酸甲酯 在 盐酸羟胺 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以98%的产率得到5-甲基异恶唑-3-羧酸甲酯
  参考文献：
  名称：

  虚拟筛选和晶体学研究揭示了一种意想不到的 γ-内酯衍生物，对 MptpB 具有活性，可作为潜在的抗结核药物

  摘要：

  分枝杆菌耐药性是一种迅速增加的现象，需要鉴定对多重耐药病原体有效的新药。抑制干扰宿主免疫反应的蛋白酪氨酸磷酸酶 B (MptpB) 可能为抗击结核病 (TB) 提供新策略，同时防止交叉耐药问题。在此基础上，从虚拟筛选 (VS) 活动和随后由 X 射线分析指导的结构解析研究开始，鉴定出一种意想不到的 γ-内酯衍生物（化合物1），它对 MptpB 具有显着的酶活性。化合物1的结构表征通过 NMR 光谱、HRMS、单晶 X 射线衍射和 Hirshfeld 表面分析进行了描述，从而可以进行详细的构象研究。值得注意的是，(±) -1的 HPLC 分离导致分离出最活跃的异构体，它作为一种非常有前途的 MptpB 抑制剂出现，IC 50值为 31.1 μM。总体而言，本文所述的新化学型可作为开发针对 TB 感染的新疗法的基础。

  DOI：

  10.1016/j.ejmech.2022.114235

文献信息

• [EN] AGONISTS OF GPR40<br/>[FR] AGONISTES DE GPR40
  申请人：CONNEXIOS LIFE SCIENCES PVT LTD

  公开号：WO2012011125A1

  公开（公告）日：2012-01-26

  The present invention relates to compounds that have the ability to modulate the activity of GPR40 and are therefore useful in the treatment of GPR40 related disorders. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders related to GPR40 activity.

  本发明涉及具有调节GPR40活性能力的化合物，因此在治疗与GPR40相关的疾病方面具有用处。此外，该发明涉及这些化合物、其制备方法、含有这些化合物的药物组合物以及在治疗与GPR40活性相关的某些疾病方面使用这些化合物的用途。
• [EN] (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING<br/>[FR] DÉRIVÉS DE (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE ET COMPOSÉS ASSOCIÉS UTILISÉS EN TANT QU'INHIBITEURS DE LA BÊTA-SÉCRÉTASE POUR LE TRAITEMENT
  申请人：COMENTIS INC

  公开号：WO2009042694A1

  公开（公告）日：2009-04-02

  The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease. (Formula)

  本发明提供了新颖的β-分泌酶抑制剂及其使用方法，包括用于治疗阿尔茨海默病的方法。
• 羟基嘌呤类化合物及其应用
  申请人：广东众生睿创生物科技有限公司

  公开号：CN105566324B

  公开（公告）日：2020-04-03

  本发明公开了一系列羟基嘌呤类化合物及其作为PDE2或TNFa抑制剂的应用，具体公开了式(Ⅰ)所示化合物、其互变异构体或其药学上可接受的盐。
• PYRAZOLO-PYRIMIDINE COMPOUNDS
  申请人：YAMAMOTO Takashi

  公开号：US20110294781A1

  公开（公告）日：2011-12-01

  The present invention has searched for a variety of compounds which show IL-12/IL-23 production-inhibitory activities and herein provides a pharmaceutical composition and an agent for preventing or treating IL-12/IL-23 excess production-related diseases, which comprise the compound.

  本发明已经寻找到多种显示IL-12/IL-23产生抑制活性的化合物，并在此提供了包括该化合物的用于预防或治疗IL-12/IL-23过度产生相关疾病的药物组合物和药剂。
• Di-heterocyclic compounds and their use as antiviral agents
  申请人：Sterling Drug Inc.

  公开号：US04843087A1

  公开（公告）日：1989-06-27

  Compounds of the formulas: ##STR1## wherein Het is an oxazole or oxazine moiety; X is O, S or SO, n is an integer from 3 to 9, Y is an aliphatic bridge; and the various R groups represent hydrogen or various substituents as described herein, are useful as antiviral agents, especially against picornaviruses. N-(Chloroalkyl)amide intermediates for the compounds of Formula I are also active as antiviral agents. Related compounds outside the scope of the above formulas are also disclosed.

  公式化合物：##STR1## 其中Het是噁唑或噁唑啉基团；X是O、S或SO，n是从3到9的整数，Y是脂肪桥；各种R基团代表氢或如本文所述的各种取代基，可用作抗病毒剂，特别是对抗小RNA病毒。用于公式I化合物的N-(氯烷基)酰胺中间体也作为抗病毒剂活性。还披露了超出上述公式范围的相关化合物。

表征谱图